# Bevacizumab in Metastatic Renal Cancer

> **NCT02627144** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 365 (actual)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Interferon alpha-2a

## Key facts

- **NCT ID:** NCT02627144
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2016-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02627144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02627144, "Bevacizumab in Metastatic Renal Cancer". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT02627144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*